Prospect on medical treatment of pulmonary mucinous adenocarcinoma / 中国综合临床
Clinical Medicine of China
;
(12): 241-245, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-992497
ABSTRACT
Pulmonary mucinous adenocarcinoma is a subtype of lung adenocarcinoma, among which invasive mucinous adenocarcinoma (IMA) is the most common subtype and is easily misdiagnosed as pneumonia. Its etiology and pathogenesis are unclear and may be related to gene mutations and other factors. Due to its relative rarity and few related studies, guidelines do not provide advices on its treatment. KRAS mutations are common in IMA patients, and Sotorasib may be effective against KRAS G12C mutated IMA. NRG1 fusion is considered to be an important driver of IMA, and afatinib may be effective in treating IMA with NRG1 fusion/rearrangement. PD-L1 expression is very low in IMA patients, while B7-H3 expression is high, so B7-H3 may be a potential immunotherapeutic target.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Clinical Medicine of China
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS